Search for content, post, videos

AstraZeneca issues a commitment for COVID-19 vaccine

Pascal Soriot

AstraZeneca is issuing a commitment to the highest safety standards and to broad and equitable access around the world for its COVID-19 vaccine AZD1222, it states.

Follow the science and put patients first

At the heart of AstraZeneca’s core values is to “follow the science” and adhere to the highest scientific and clinical standards, making the safety and efficacy of the vaccine of paramount importance. The company’s submissions for market authorization will meet the stringent requirements established by regulators everywhere around the world.

Read more: AstraZeneca expands its US COVID-19 vaccine trial

“In recent weeks we have seen an increasing number of questions around the safety and availability of vaccines to fight this terrible COVID-19 pandemic and I want to reiterate my commitment that we are putting science and the interest of society at the heart of our work.”

The company also has a core value to “put patients first” and will continue to work with governments and other organisations towards broad and equitable global access to the vaccine, scaling up manufacturing with independent parallel supply chains around the world to produce billions of doses to a consistent and high standard of safety and efficacy, it states.

“In recent weeks we have seen an increasing number of questions around the safety and availability of vaccines to fight this terrible COVID-19 pandemic and I want to reiterate my commitment that we are putting science and the interest of society at the heart of our work. We are moving quickly but without cutting corners, and regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes this potential COVD-19 vaccine. We will remain true to our values as we continue our efforts to bring this vaccine broadly and equitably to billions of people around world,” says Pascal Soriot, Chief Executive Officer, AstraZeneca.

Photo of Pascal Soriot: AstraZeneca